REFERENCES
1. Sharifzad F, Ghavami S, Verdi J, Mardpour S, Mollapour Sisakht M, et al. Glioblastoma cancer stem cell biology: potential theranostic targets. Drug Resist Updat 2019;42:35-45.
2. Akbari-Birgani S, Paranjothy T, Zuse A, Janikowski T, Cieślar-Pobuda A, et al. Cancer stem cells, cancer-initiating cells and methods for their detection. Drug Discov Today 2016;21:836-42.
3. Farahani E, Patra HK, Jangamreddy JR, Rashedi I, Kawalec M, et al. Cell adhesion molecules and their relation to (cancer) cell stemness. Carcinogenesis 2014;35:747-59.
4. Hombach-Klonisch S, Mehrpour M, Shojaei S, Harlos C, Pitz M, et al. Glioblastoma and chemoresistance to alkylating agents: involvement of apoptosis, autophagy, and unfolded protein response. Pharmacol Ther 2018;184:13-41.
5. Wasik AM, Grabarek J, Pantovic A, Cieślar-Pobuda A, Asgari HR, et al. Reprogramming and carcinogenesis-parallels and distinctions. Int Rev Cell Mol Biol 2014;308:167-203.
6. Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, et al. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 2010;70:7500-13.
7. Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep 2013;13:345.
8. Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer 2015;15:302-10.
9. Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, et al. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget 2016;7:65696-706.
10. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
11. de Toledo SM, Azzam EI, Dahlberg WK, Gooding TB, Little JB. ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation. Oncogene 2000;19:6185-93.
12. Lathia JD, Liu H. Overview of cancer stem cells and stemness for community oncologists. Target Oncol 2017;12:387-99.
13. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al; Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510-22.
14. Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, et al. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 2006;4:709-14.
15. Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer 2017;16:100.
16. Beck S, Jin X, Sohn YW, Kim JK, Kim SH, et al. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. Mol Cells 2011;31:9-15.
17. Benitez JA, Ma J, D’antonio M, Boyer A, Camargo MF, et al. PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nat Commun 2017;8:15223.
18. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008;455:1129-33.
19. Daniele S, Taliani S, Da Pozzo E, Giacomelli C, Costa B, et al. Apoptosis therapy in cancer: the first single-molecule co-activating p53 and the translocator protein in glioblastoma. Sci Rep 2014;4:4749.
20. Kanamori M, Suzuki H, Takei H, Sonoda Y, Uenohara H, et al. Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation. Brain Tumor Pathol 2016;33:50-6.
21. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
22. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
24. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012;482:226-31.
25. Cenciarelli C, Marei HE, Felsani A, Casalbore P, Sica G, et al. Correction: PDGFRα depletion attenuates glioblastoma stem cells features by modulation of STAT3, RB1 and multiple oncogenic signals. Oncotarget 2017;8:36931.
26. Kaminska B, Cyranowski S. Recent advances in understanding mechanisms of TGFβ signaling and its role in glioma pathogenesis. In: Barańska J, editor. Glioma signaling. Cham: Springer International Publishing; 2020. pp. 179-201.
27. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-β signaling. J Cell Biochem 2007;101:9-33.
28. Budi EH, Duan D, Derynck R. Transforming growth factor-β receptors and Smads: regulatory complexity and functional versatility. Trends Cell Biol 2017;27:658-72.
29. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425:577-84.
30. Itoh S, ten Dijke P. Negative regulation of TGF-β receptor/Smad signal transduction. Curr Opin Cell Biol 2007;19:176-84.
31. Hau P, Jachimczak P, Schlaier J, Bogdahn U. TGF-β2 signaling in high-grade gliomas. Curr Pharm Biotechnol 2011;12:2150-7.
32. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, et al. High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007;11:147-60.
33. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, et al. Autocrine TGF-β signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009;5:504-14.
34. Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, et al. TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009;15:315-27.
35. Beck C, Schreiber H, Rowley DA. Role of TGF-β in immune-evasion of cancer. Microsc Res Tech 2001;52:387-95.
36. Sánchez-Elsner T, Botella LM, Velasco B, Corbí A, Attisano L, et al. Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001;276:38527-35.
37. Wick W, Platten M, Weller M. Glioma cell invasion: regulation of metalloproteinase activity by TGF-β. J Neurooncol 2001;53:177-85.
38. Dietrich LC, Mellberg S, Langenkamp E, Zhang L, Zieba A, et al. Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFβ2 in vascular abnormalization. J Pathol 2012;228:378-90.
39. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFß and BMP pathways. Cell Signal 2011;23:1831-42.
40. Towner RA, Smith N, Saunders D, Brown CA, Cai X, et al. OKN-007 increases temozolomide (TMZ) sensitivity and suppresses TMZ-resistant glioblastoma (GBM) tumor growth. Transl Oncol 2019;12:320-35.
41. Roy LO, Poirier MB, Fortin D. Differential expression and clinical significance of transforming growth factor-β isoforms in GBM tumors. Int J Mol Sci 2018;19:1113.
42. Cao Z, Kyprianou N. Mechanisms navigating the TGF-β pathway in prostate cancer. Asian J Urol 2015;2:11-8.
43. Zhu B, Kyprianou N. Transforming growth factor β and prostate cancer. In: Platanias LC, editor. Cytokines and cancer. New York: Springer-Verlag; 2005. pp. 157-73.
44. Conery AR, Cao Y, Thompson EA, Townsend CM Jr, Ko TC, et al. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β induced apoptosis. Nat Cell Biol 2004;6:366-72.
45. Akhurst RJ, Derynck R. TGF-β signaling in cancer - a double-edged sword. Trends in Cell Biology 2001;11:S44-51.
46. Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity 2011;35:123-34.
47. Jones E, Pu H, Kyprianou N. Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets 2009;13:227-34.
48. Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, et al. Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol 2010;36:1367-77.
49. Wang Z, Wang K, Wang R, Liu X. SUMOylation regulates TGF-β1/Smad4 signalling in-resistant glioma cells. Anticancer Drugs 2017; doi: 10.1097/CAD.0000000000000578.
51. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
53. Gagliardi PA, Puliafito A, Primo L. PDK1: at the crossroad of cancer signaling pathways. Semin Cancer Biol 2018;48:27-35.
54. Haas B, Klinger V, Keksel C, Bonigut V, Kiefer D, et al. Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer Cell Int 2018;18:69.
55. Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol 2012;14:819-29.
56. Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013;12:86.
58. Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res 2014;2:823-30.
59. Bhat KLP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 2013;24:331-46.
60. Rinkenbaugh AL, Cogswell PC, Calamini B, Dunn DE, Persson AI, et al. IKK/NF-κB signaling contributes to glioblastoma stem cell maintenance. Oncotarget 2016;7:69173-87.
61. Yu Z, Chen Y, Wang S, Li P, Zhou G, et al. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression. Cancer Letters 2018;428:77-89.
62. Cheng F, Guo D. MET in glioma: signaling pathways and targeted therapies. J Exp Clin Cancer Res 2019;38:270.
63. Huang M, Liu T, Ma P, Mitteer RA Jr, Zhang Z, et al. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J Clin Invest 2016;126:1801-14.
64. Li J, Li Q, Lin L, Wang R, Chen L, et al. Targeting the Notch1 oncogene by miR-139-5p inhibits glioma metastasis and epithelial-mesenchymal transition (EMT). BMC Neurol 2018;18:133.
65. Bazzoni R, Bentivegna A. Role of Notch signaling pathway in glioblastoma pathogenesis. Cancers (Basel) 2019;11:292.
66. Gersey Z, Osiason AD, Bloom L, Shah S, Thompson JW, et al. Therapeutic Targeting of the Notch Pathway in Glioblastoma Multiforme. World Neurosurg 2019;131:252-63.e2.
67. Venkatesh V, Nataraj R, Thangaraj GS, Karthikeyan M, Gnanasekaran A, et al. Targeting Notch signalling pathway of cancer stem cells. Stem Cell Investig 2018;5:5.
68. Shih AH, Holland EC. Notch signaling enhances nestin expression in gliomas. Neoplasia 2006;8:1072-82.
69. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, et al. Inhibition of Notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010;28:1019-29.
70. Li WB, Ma MW, Dong LJ, Wang F, Chen LX, et al. MicroRNA-34a targets Notch1 and inhibits cell proliferation in glioblastoma multiforme. Cancer Biol Ther 2011;12:477-83.
71. Hai L, Zhang C, Li T, Zhou X, Liu B, et al. Notch1 is a prognostic factor that is distinctly activated in the classical and proneural subtype of glioblastoma and that promotes glioma cell survival via the NF-κB(p65) pathway. Cell Death Dis 2018;9:158.
72. Floyd DH, Kefas B, Seleverstov O, Mykhaylyk O, Dominguez C, et al. Alpha-secretase inhibition reduces human glioblastoma stem cell growth
73. Hellström M, Phng LK, Gerhardt H. VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adh Migr 2007;1:133-6.
74. Zalles M, Smith N, Ziegler J, Saunders D, Remerowski S, et al. Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model. J Cell Mol Med 2020;24:1738-49.
75. Masiero M, Simões FC, Han HD, Snell C, Peterkin T, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 2013;24:229-41.
76. Zalles M, Smith N, Saunders D, Saran T, Thomas L, et al. Assessment of an scFv antibody fragment against ELTD1 in a G55 glioblastoma xenograft model. Transl Oncol 2020;13:100737.
77. Favara DM, Zois CE, Haider S, Pires E, Sheldon H, et al. ADGRL4/ELTD1 silencing in endothelial cells induces ACLY and SLC25A1 and alters the cellular metabolic profile. Metabolites 2019;9:287.
78. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, et al; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77.
79. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985;313:144-7.
80. Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 2013;24:438-49.
81. Klingler S, Guo B, Yao J, Yan H, Zhang L, et al. Development of resistance to EGFR-targeted therapy in malignant gliomacan occur through EGFR-dependent and -independent mechanisms. Cancer Res 2015;75:2109-19.
82. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
83. Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006;12:860-8.
84. Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 2009;92:99-105.
85. Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci 2016;19:20-7.
86. Schiffer D, Annovazzi L, Casalone C, Corona C, Mellai M. Glioblastoma: microenvironment and niche concept. Cancers (Basel) 2018;11:5.
87. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84-8.
88. Zhao W, Liu M, Kirkwood KL. p38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements. J Biol Chem 2008;283:1778-85.
89. David CJ, Massagué J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol 2018;19:419-35.
90. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015;523:231-5.
91. Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res 2019;25:4202-10.
92. Zhang X, Ding K, Wang J, Li X, Zhao P. Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions. Biomed Pharmacother 2019;109:39-46.
93. Guan X, Hasan MN, Maniar S, Jia W, Sun D. Reactive astrocytes in glioblastoma multiforme. Mol Neurobiol 2018;55:6927-38.
94. D’Alessio A, Proietti G, Sica G, Scicchitano BM. Pathological and molecular features of glioblastoma and its peritumoral tissue. Cancers (Basel) 2019;11:469.
95. Placone AL, Quiñones-Hinojosa A, Searson PC. The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment. Tumour Biol 2016;37:61-9.
96. Munoz JL, Rodriguez-Cruz V, Greco SJ, Ramkissoon SH, Ligon KL, et al. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis 2014;5:e1145.
97. Da Ros M, De Gregorio V, Iorio AL, Giunti L, Guidi M, et al. Glioblastoma chemoresistance: the double play by microenvironment and blood-brain barrier. Int J Mol Sci 2018;19:2879.
98. Barbero S, Bajetto A, Bonavia R, Porcile C, Piccioli P, et al. Expression of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 in human brain tumors and their involvement in glial proliferation in vitro. Ann N Y Acad Sci 2002;973:60-9.
99. Sin WC, Aftab Q, Bechberger JF, Leung JH, Chen H, et al. Astrocytes promote glioma invasion via the gap junction protein connexin43. Oncogene 2016;35:1504-16.
100. Fioretti B, Castigli E, Micheli MR, Bova R, Sciaccaluga M, et al. Expression and modulation of the intermediate- conductance Ca2+-activated K+ channel in glioblastoma GL-15 cells. Cell Physiol Biochem 2006;18:47-56.
101. Sciaccaluga M, Fioretti B, Catacuzzeno L, Pagani F, Bertollini C, et al. CXCL12-induced glioblastoma cell migration requires intermediate conductance Ca2+-activated K+ channel activity. Am J Physiol Cell Physiol 2010;299:C175-84.
102. Stegen B, Butz L, Klumpp L, Zips D, Dittmann K, et al. Ca2+-Activated IK K+ channel blockade radiosensitizes glioblastoma cells. Mol Cancer Res 2015;13:1283-95.
103. Morrone FB, Gehring MP, Nicoletti NF. Calcium channels and associated receptors in malignant brain tumor therapy. Mol Pharmacol 2016;90:403-9.
104. Costanza B, Umelo IA, Bellier J, Castronovo V, Turtoi A. Stromal modulators of TGF-β in cancer. J Clin Med 2017;6:7.
